Concepts (188)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vaccines | 11 | 2022 | 225 | 1.810 |
Why?
|
| Vaccination | 18 | 2026 | 725 | 1.180 |
Why?
|
| Whooping Cough | 4 | 2022 | 71 | 0.970 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 3 | 2022 | 98 | 0.890 |
Why?
|
| Diphtheria | 2 | 2022 | 13 | 0.820 |
Why?
|
| Tetanus | 2 | 2022 | 23 | 0.810 |
Why?
|
| Humans | 46 | 2026 | 16832 | 0.770 |
Why?
|
| Cataplexy | 1 | 2022 | 6 | 0.720 |
Why?
|
| Narcolepsy | 1 | 2022 | 8 | 0.720 |
Why?
|
| Bell Palsy | 1 | 2022 | 14 | 0.720 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 17 | 0.710 |
Why?
|
| Retrospective Studies | 17 | 2022 | 2463 | 0.670 |
Why?
|
| Myocardial Infarction | 4 | 2022 | 215 | 0.580 |
Why?
|
| Cohort Studies | 10 | 2022 | 2396 | 0.520 |
Why?
|
| Asthma | 3 | 2020 | 375 | 0.510 |
Why?
|
| Blood Cells | 1 | 2016 | 3 | 0.490 |
Why?
|
| Adult | 20 | 2023 | 7255 | 0.490 |
Why?
|
| Female | 27 | 2026 | 12193 | 0.490 |
Why?
|
| Eosinophils | 1 | 2016 | 10 | 0.490 |
Why?
|
| Infant | 10 | 2022 | 1212 | 0.480 |
Why?
|
| Male | 24 | 2026 | 9556 | 0.450 |
Why?
|
| Herpes Zoster Vaccine | 3 | 2021 | 60 | 0.410 |
Why?
|
| Seizures, Febrile | 4 | 2022 | 42 | 0.400 |
Why?
|
| Aged | 18 | 2026 | 5901 | 0.390 |
Why?
|
| Hospitalization | 7 | 2022 | 816 | 0.380 |
Why?
|
| Pandemics | 4 | 2022 | 289 | 0.370 |
Why?
|
| United States | 14 | 2026 | 3858 | 0.360 |
Why?
|
| Delivery of Health Care, Integrated | 4 | 2021 | 515 | 0.340 |
Why?
|
| Middle Aged | 17 | 2021 | 7515 | 0.340 |
Why?
|
| Adolescent | 12 | 2023 | 3464 | 0.330 |
Why?
|
| Influenza, Human | 3 | 2022 | 292 | 0.320 |
Why?
|
| Natural Language Processing | 3 | 2022 | 60 | 0.320 |
Why?
|
| Stroke | 3 | 2022 | 297 | 0.310 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2022 | 353 | 0.310 |
Why?
|
| Outpatients | 2 | 2021 | 99 | 0.310 |
Why?
|
| Herpes Zoster | 2 | 2021 | 80 | 0.280 |
Why?
|
| Hepatitis B Vaccines | 2 | 2020 | 44 | 0.260 |
Why?
|
| Incidence | 5 | 2022 | 1229 | 0.260 |
Why?
|
| Case-Control Studies | 4 | 2023 | 995 | 0.250 |
Why?
|
| Databases, Factual | 3 | 2019 | 294 | 0.250 |
Why?
|
| Infant, Newborn | 4 | 2022 | 828 | 0.240 |
Why?
|
| Young Adult | 11 | 2021 | 2456 | 0.240 |
Why?
|
| Influenza Vaccines | 4 | 2019 | 300 | 0.240 |
Why?
|
| Aged, 80 and over | 9 | 2026 | 1887 | 0.230 |
Why?
|
| Measles Vaccine | 2 | 2022 | 17 | 0.210 |
Why?
|
| California | 9 | 2022 | 2244 | 0.210 |
Why?
|
| Prospective Studies | 4 | 2023 | 1186 | 0.200 |
Why?
|
| Models, Statistical | 2 | 2014 | 164 | 0.190 |
Why?
|
| Typhoid-Paratyphoid Vaccines | 1 | 2022 | 3 | 0.190 |
Why?
|
| Travel | 1 | 2022 | 10 | 0.190 |
Why?
|
| Corynebacterium | 1 | 2022 | 3 | 0.180 |
Why?
|
| Shoulder Injuries | 1 | 2022 | 2 | 0.180 |
Why?
|
| Latent Tuberculosis | 1 | 2022 | 13 | 0.180 |
Why?
|
| Placenta | 1 | 2022 | 20 | 0.180 |
Why?
|
| Tuberculosis | 1 | 2022 | 23 | 0.180 |
Why?
|
| Orthopedic Procedures | 1 | 2022 | 6 | 0.180 |
Why?
|
| Anaphylaxis | 2 | 2019 | 15 | 0.180 |
Why?
|
| Child, Preschool | 8 | 2021 | 1430 | 0.180 |
Why?
|
| Measles | 1 | 2022 | 25 | 0.170 |
Why?
|
| Child | 8 | 2022 | 2433 | 0.170 |
Why?
|
| Politics | 1 | 2020 | 9 | 0.160 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2020 | 12 | 0.160 |
Why?
|
| Inpatients | 1 | 2021 | 78 | 0.160 |
Why?
|
| Diabetes Complications | 1 | 2021 | 93 | 0.160 |
Why?
|
| Urinary Tract Infections | 1 | 2020 | 16 | 0.160 |
Why?
|
| Hepatitis B | 1 | 2020 | 43 | 0.160 |
Why?
|
| Betacoronavirus | 1 | 2020 | 36 | 0.160 |
Why?
|
| Vaccination Coverage | 1 | 2021 | 68 | 0.150 |
Why?
|
| Emergency Service, Hospital | 2 | 2021 | 393 | 0.150 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 374 | 0.150 |
Why?
|
| Ischemia | 1 | 2019 | 4 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 49 | 0.150 |
Why?
|
| Peripheral Arterial Disease | 1 | 2019 | 13 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 56 | 0.150 |
Why?
|
| Autism Spectrum Disorder | 1 | 2022 | 165 | 0.150 |
Why?
|
| Recurrence | 2 | 2016 | 149 | 0.150 |
Why?
|
| Stress, Psychological | 1 | 2020 | 136 | 0.150 |
Why?
|
| Risk | 3 | 2020 | 453 | 0.150 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 157 | 0.150 |
Why?
|
| Pregnancy | 2 | 2022 | 1555 | 0.150 |
Why?
|
| Hypertension | 2 | 2020 | 475 | 0.140 |
Why?
|
| Pain | 1 | 2019 | 65 | 0.140 |
Why?
|
| Dyslipidemias | 1 | 2019 | 57 | 0.140 |
Why?
|
| Disease Progression | 2 | 2016 | 252 | 0.140 |
Why?
|
| Telemedicine | 1 | 2021 | 190 | 0.130 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 155 | 0.130 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 213 | 0.130 |
Why?
|
| Medicare Part D | 1 | 2017 | 17 | 0.130 |
Why?
|
| Cost Sharing | 1 | 2017 | 28 | 0.130 |
Why?
|
| Treatment Outcome | 2 | 2019 | 1098 | 0.130 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 290 | 0.130 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 520 | 0.130 |
Why?
|
| Cell Count | 1 | 2016 | 9 | 0.120 |
Why?
|
| Heart Failure | 1 | 2022 | 403 | 0.120 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2016 | 55 | 0.120 |
Why?
|
| Perioperative Period | 1 | 2016 | 5 | 0.120 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2016 | 85 | 0.120 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2015 | 6 | 0.120 |
Why?
|
| Biomarkers | 1 | 2016 | 284 | 0.110 |
Why?
|
| Immunization Schedule | 3 | 2021 | 127 | 0.110 |
Why?
|
| Pregnancy Outcome | 1 | 2016 | 160 | 0.110 |
Why?
|
| Premature Birth | 1 | 2016 | 133 | 0.110 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2014 | 7 | 0.110 |
Why?
|
| Obesity | 1 | 2020 | 811 | 0.100 |
Why?
|
| Risk Factors | 5 | 2020 | 3108 | 0.100 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2016 | 158 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 677 | 0.100 |
Why?
|
| Algorithms | 3 | 2022 | 210 | 0.100 |
Why?
|
| Models, Theoretical | 1 | 2014 | 66 | 0.100 |
Why?
|
| Computer Simulation | 1 | 2014 | 84 | 0.100 |
Why?
|
| Biometry | 1 | 2014 | 13 | 0.100 |
Why?
|
| Health Care Costs | 1 | 2015 | 192 | 0.100 |
Why?
|
| Safety | 1 | 2014 | 43 | 0.100 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 1058 | 0.100 |
Why?
|
| Time Factors | 4 | 2019 | 989 | 0.100 |
Why?
|
| Papillomavirus Vaccines | 1 | 2014 | 113 | 0.100 |
Why?
|
| Multiple Sclerosis | 1 | 2014 | 98 | 0.090 |
Why?
|
| HIV Infections | 1 | 2019 | 708 | 0.090 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 67 | 0.090 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2012 | 97 | 0.090 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2012 | 104 | 0.090 |
Why?
|
| Age Factors | 3 | 2020 | 814 | 0.090 |
Why?
|
| Vaccines, Combined | 2 | 2022 | 80 | 0.080 |
Why?
|
| Fever | 2 | 2022 | 52 | 0.070 |
Why?
|
| Observational Studies as Topic | 2 | 2020 | 44 | 0.070 |
Why?
|
| Sex Factors | 2 | 2020 | 560 | 0.070 |
Why?
|
| Immunization Programs | 2 | 2020 | 65 | 0.060 |
Why?
|
| Comorbidity | 2 | 2020 | 516 | 0.060 |
Why?
|
| Vaccines, Inactivated | 2 | 2019 | 73 | 0.060 |
Why?
|
| Prevalence | 2 | 2021 | 785 | 0.060 |
Why?
|
| Maternal Age | 2 | 2016 | 73 | 0.060 |
Why?
|
| Managed Care Programs | 2 | 2017 | 275 | 0.050 |
Why?
|
| Medicare | 1 | 2026 | 188 | 0.050 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2016 | 99 | 0.050 |
Why?
|
| Electronic Health Records | 2 | 2019 | 702 | 0.050 |
Why?
|
| Travel-Related Illness | 1 | 2022 | 3 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2023 | 66 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 37 | 0.050 |
Why?
|
| Acute Disease | 1 | 2022 | 144 | 0.040 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2022 | 64 | 0.040 |
Why?
|
| Aftercare | 1 | 2022 | 46 | 0.040 |
Why?
|
| Chickenpox Vaccine | 1 | 2022 | 91 | 0.040 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2020 | 9 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2021 | 19 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 2021 | 39 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 104 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2020 | 43 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 80 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2022 | 152 | 0.040 |
Why?
|
| Neuralgia, Postherpetic | 1 | 2019 | 11 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 29 | 0.040 |
Why?
|
| Drug Utilization | 1 | 2019 | 112 | 0.040 |
Why?
|
| Herpesvirus 3, Human | 1 | 2019 | 40 | 0.040 |
Why?
|
| Critical Illness | 1 | 2019 | 53 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2020 | 278 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2020 | 205 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 145 | 0.040 |
Why?
|
| Viral Load | 1 | 2019 | 141 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2019 | 155 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 410 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 311 | 0.030 |
Why?
|
| Pregnancy Trimesters | 1 | 2016 | 27 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2016 | 12 | 0.030 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2016 | 56 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 445 | 0.030 |
Why?
|
| Bias | 1 | 2016 | 90 | 0.030 |
Why?
|
| Infection | 1 | 2016 | 17 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2020 | 925 | 0.030 |
Why?
|
| Propensity Score | 1 | 2016 | 78 | 0.030 |
Why?
|
| Seasons | 1 | 2016 | 114 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 84 | 0.030 |
Why?
|
| Epilepsy | 1 | 2014 | 14 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2014 | 45 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2014 | 84 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2016 | 161 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2014 | 261 | 0.030 |
Why?
|
| Gestational Age | 1 | 2014 | 118 | 0.020 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2013 | 15 | 0.020 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2013 | 18 | 0.020 |
Why?
|
| Vaccines, Conjugate | 1 | 2013 | 59 | 0.020 |
Why?
|
| Vaccines, Acellular | 1 | 2012 | 11 | 0.020 |
Why?
|
| Quality Control | 1 | 2012 | 37 | 0.020 |
Why?
|
| Off-Label Use | 1 | 2012 | 13 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2014 | 569 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 489 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 657 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2016 | 1047 | 0.020 |
Why?
|
| Ethnic Groups | 1 | 2014 | 418 | 0.020 |
Why?
|
Concepts
(188)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(30)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_
-->